On-Demand Webcast

Share

Program Content

Activities

  • HER2-Targeted Therapy for NSCLC
    Improving Outcomes for Patients With Advanced NSCLC Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 01, 2023

    Expires: November 30, 2024

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.